Bracket to Introduce New eCOA Platform at DIA Meeting
The tool is the first electronic clinical outcome assessment product of its kind to fully integrate with RTSM
Wayne, PA – Bracket, a leading clinical trial technology and specialty services provider, will launch its next generation clinical outcomes platform, Bracket eCOASM 6.0, at the 52nd Annual DIA Meeting held on June 26 – 30 in Philadelphia, Pennsylvania. A demonstration of eCOA 6.0, the first electronic clinical outcome assessment product of its kind to fully integrate with RTSM, will be held at DIA Booth #715.
Bracket eCOA 6.0 is a flexible platform for electronic clinical outcomes assessments that is driving digitization in clinical trials. The platform integrates with industry-leading Samsung Galaxy smartphones and
Microsoft’s Surface Pro Windows tablets to support ePro, eClinRO, and eObsRO, and features fully integrated clinician and patient-facing tools, to ensure the experience is fully harmonized for any user.
“Bracket eCOA combines science and technology to collect patient information through smartphones or tablets, and ultimately achieve higher quality outcomes and efficiency in clinical trials,” said Jeff Kinell, CEO for Bracket. “We are pleased to launch eCOA 6.0 and continue demonstrating our commitment to paper-free clinical trials as we prepare for the mobile revolution.”
The platform’s integration with industry leading Clinical IRT solution, Bracket RTSM, enables subject questionnaires that trigger enrollment eligibility and randomization to kickoff schedule of reported outcomes entries. Its advisory services support scale design, development, licensing and validation, rater training and certification, clinical review and quality assurance, data analytics, and compliance tracking.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025